Juno founders set their sights on cre­at­ing an ‘epic’ new biotech with high-rolling in­vestors at their back

Steve Harr has been busy.

Over the past 9 months or so, the for­mer Juno CFO who helped break ground on CAR-T tech has been cre­at­ing a new biotech called Sana Biotech­nol­o­gy with some big goals in mind.

Sana is jump­ing from stage right in­to what it hopes will be the cen­ter ring of next-gen tech­nol­o­gy aimed at cre­at­ing a new wave of cell and gene ther­a­pies that can be used off-the-shelf to go where need­ed to fix a va­ri­ety of dis­eases — un­bound by dis­ease fields or even hub bound­aries.

“We want to build some­thing that is epic in its im­pact on pa­tients,” says the CEO. Epic and en­dur­ing.

Harr isn’t talk­ing mon­ey right now — “you can make your own con­jec­tures” — but his 3 cur­rent back­ers tell me that mon­ey isn’t an is­sue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER